Management of the Axilla in the Setting of Neo-adjuvant Systemic Therapy-AM2019
In this session, presenters will discuss the controversies involved in radiotherapy decision-making in the era of neoadjuvant systemic therapy. Data from randomized trials will be described where available, along with the relevant strengths and limitations. Supplemental data describing factors that modify risk of recurrence and potential radiotherapy impact will also be reviewed, as will ongoing trials that may impact management of this clinical scenario in coming years. Data characterizing the relationship between chemotherapy response and locoregional control will also be reviewed. Again, priority will be given to data from randomized and/or prospective trials but other robust series will also be incorporated. The instructors will incorporate case presentations designed to illustrate salient points from the didactic presentations as appropriate.
This activity is available from January 15, 2020, through 11:59 p.m. Eastern time on January 14, 2023.
This activity was originally recorded at ASTRO’s 2019 Annual Meeting, September 15-18, 2019 in Chicago, IL.
The meeting is designed to meet the interests of radiation oncologists, medical oncologists, nurses, surgeons and residents.
- Demonstrate knowledge of relevant clinical trials and supplemental data impacting the management of patients with radiation following neoadjuvant systemic therapy.
- Determine relevant indications for radiation among patients receiving neoadjuvant chemotherapy, including consideration of ongoing clinical trials as appropriate.
- Make appropriate decisions regarding axillary management of the axilla following receipt of neoadjuvant systemic therapy, incorporating impact of patient quality-of-life.
The following persons served as faculty for this activity:
Bruce Haffty, MD, FASTRO is employed at Rutgers-CINJ-RWJMS and has nothing to disclose.
Rachel Jimenez, MD is employed at Massachusetts General Hospital and has nothing to disclose.
Monica Morrow, MD is employed at Memorial Sloan Kettering Cancer Center and has nothing to disclose.
Simona Shaitelman, MD, EdM is employed at UT MD Anderson Cancer Center and receives compensation/remuneration/funding from Varian.
Additionally, the Education and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.